allogeneic donor derived LMP-specific cytotoxic T-lymphocyte

Allogeneic donor-derived LMP-specific cytotoxic T-lymphocyte (CTL) therapy is a type of adoptive cell therapy that utilizes T-cells from a healthy donor. These T-lymphocytes are specifically engineered or selected to recognize and eliminate cells expressing Latent Membrane Proteins (LMPs) of the Epstein-Barr virus (EBV). The therapy is primarily developed for patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and are at risk of or experiencing complications such as EBV-positive post-transplantation lymphoproliferative disease (PTLD) or leukemia relapse. The CTLs are typically generated ex vivo from donor peripheral blood mononuclear cells and then infused intravenously into the patient. This approach aims to restore immune surveillance against EBV-infected or malignant cells, leveraging the graft-versus-malignancy effect while minimizing the risk of graft-versus-host disease.